Skip to main content
Premium Trial:

Request an Annual Quote

LabNow Lands $20M Series B to Develop, Launch HIV/AIDS Assay

NEW YORK (GenomeWeb News) - Point-of-care diagnostics developer LabNow said yesterday that it has landed $20 million in Series B equity financing from private and venture investors. 
 
LabNow will use the money for the late-stage development and launch of its CD4Now Biochip and Analyzer device, a CD4 testing system for use in the assessment and treatment of HIV/AIDS patients.
 
The funding was led by Austin Ventures and Sammons Enterprises, both Texas-based investors that also backed LabNow’s Series A financing, and includes a group of other private investors, the company said.
 
LabNow, based in Austin, Texas, said its sensor technology analyzes blood and other fluid samples “simply, rapidly, and economically,” and shows promise for healthcare applications as well as environmental and food safety testing and in homeland security applications.
 
The company said the CD4Now system uses an automated reader and assay-specific disposable chips to generate accurate CD4 cell counts in less than 15 minutes from a single drop of blood.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.